-
Product Insights
NewNet Present Value Model: Merus NV’s Zenocutuzumab
Empower your strategies with our Net Present Value Model: Merus NV's Zenocutuzumab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Merus NV’s Petosemtamab
Empower your strategies with our Net Present Value Model: Merus NV's Petosemtamab report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Meru County Wind Farm
Meru County Wind Farm is an onshore wind project located in Meru, Kenya. The project is owned and developed by Eurus Energy Holdings Corp; Meru County Investment and Development Corp; Windlab Pty Ltd. The project is currently under construction. Empower your strategies with our Meru County Wind Farm report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the...
-
Product Insights
Meru County Solar PV Park
Meru County Solar PV Park is a solar PV project located in Meru, Kenya. The project is owned and developed by Eurus Energy Holdings Corp; Windlab Pty Ltd. The project is currently under construction. Empower your strategies with our Meru County Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and...
-
Product Insights
NewNet Present Value Model: Merus NV’s MCLA-145
Empower your strategies with our Net Present Value Model: Merus NV's MCLA-145 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Merus NV Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Merus NV Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewNet Present Value Model: Simcere Pharmaceutical Group Ltd’s (Borneol + Edaravone)
Empower your strategies with our Net Present Value Model: Simcere Pharmaceutical Group Ltd's (Borneol + Edaravone) report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Pfizer Inc’s Sasanlimab
Empower your strategies with our Net Present Value Model: Pfizer Inc's Sasanlimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MCLA-129 in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MCLA-129 in Laryngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MCLA-129 in Laryngeal Cancer Drug Details: MCLA-129 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MCLA-129 in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MCLA-129 in Oropharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MCLA-129 in Oropharyngeal Cancer Drug Details: MCLA-129 is under development for the...